P
12.36
0.08 (0.65%)
| Penutupan Terdahulu | 12.28 |
| Buka | 12.75 |
| Jumlah Dagangan | 1,012,731 |
| Purata Dagangan (3B) | 3,884,111 |
| Modal Pasaran | 1,319,440,896 |
| Harga / Jualan (P/S) | 17.35 |
| Harga / Buku (P/B) | 5.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -98.10% |
| Margin Operasi (TTM) | -85.88% |
| EPS Cair (TTM) | -1.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.81% |
| Nisbah Semasa (MRQ) | 6.91 |
| Aliran Tunai Operasi (OCF TTM) | -42.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -23.09 M |
| Pulangan Atas Aset (ROA TTM) | -17.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Personalis, Inc. | Bercampur | Menaik |
AISkor Stockmoo
-1.3
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.33 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 31.49% |
| % Dimiliki oleh Institusi | 46.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Merck & Co., Inc. | 31 Mar 2026 | 14,044,943 |
| Blue Water Life Science Advisors, Lp | 31 Mar 2026 | 1,676,300 |
| Casdin Capital, Llc | 31 Mar 2026 | 1,600,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |